1
|
Lebrun LJ, Pallot G, Nguyen M, Tavernier A, Dusuel A, Pilot T, Deckert V, Dugail I, Le Guern N, Pais De Barros JP, Benkhaled A, Choubley H, Lagrost L, Masson D, Gautier T, Grober J. Increased Weight Gain and Insulin Resistance in HF-Fed PLTP Deficient Mice Is Related to Altered Inflammatory Response and Plasma Transport of Gut-Derived LPS. Int J Mol Sci 2022; 23:13226. [PMID: 36362012 PMCID: PMC9654699 DOI: 10.3390/ijms232113226] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 10/24/2022] [Accepted: 10/26/2022] [Indexed: 11/15/2023] Open
Abstract
Bacterial lipopolysaccharides (LPS, endotoxins) are found in high amounts in the gut lumen. LPS can cross the gut barrier and pass into the blood (endotoxemia), leading to low-grade inflammation, a common scheme in metabolic diseases. Phospholipid transfer protein (PLTP) can transfer circulating LPS to plasma lipoproteins, thereby promoting its detoxification. However, the impact of PLTP on the metabolic fate and biological effects of gut-derived LPS is unknown. This study aimed to investigate the influence of PLTP on low-grade inflammation, obesity and insulin resistance in relationship with LPS intestinal translocation and metabolic endotoxemia. Wild-type (WT) mice were compared with Pltp-deficient mice (Pltp-KO) after a 4-month high-fat (HF) diet or oral administration of labeled LPS. On a HF diet, Pltp-KO mice showed increased weight gain, adiposity, insulin resistance, lipid abnormalities and inflammation, together with a higher exposure to endotoxemia compared to WT mice. After oral administration of LPS, PLTP deficiency led to increased intestinal translocation and decreased association of LPS to lipoproteins, together with an altered catabolism of triglyceride-rich lipoproteins (TRL). Our results show that PLTP, by modulating the intestinal translocation of LPS and plasma processing of TRL-bound LPS, has a major impact on low-grade inflammation and the onset of diet-induced metabolic disorders.
Collapse
Affiliation(s)
- Lorène J. Lebrun
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Institut Agro Dijon, 1 Esplanade Erasme, 21000 Dijon, France
| | - Gaëtan Pallot
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Maxime Nguyen
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Department of Anesthesiology and Intensive Care, Dijon University Hospital, 21000 Dijon, France
| | - Annabelle Tavernier
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Institut Agro Dijon, 1 Esplanade Erasme, 21000 Dijon, France
| | - Alois Dusuel
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Thomas Pilot
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Valérie Deckert
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Isabelle Dugail
- Faculté de Médecine Pitié-Salpêtrière, UMR1269, 75000 Paris, France
| | - Naig Le Guern
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Jean-Paul Pais De Barros
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Lipidomic Analytic Plate-Forme, UBFC, Bâtiment B3, 21000 Dijon, France
| | - Anissa Benkhaled
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Hélène Choubley
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Lipidomic Analytic Plate-Forme, UBFC, Bâtiment B3, 21000 Dijon, France
| | - Laurent Lagrost
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - David Masson
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Laboratory of Clinical Chemistry, François Mitterrand University Hospital, 21000 Dijon, France
| | - Thomas Gautier
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
| | - Jacques Grober
- INSERM, LNC UMR1231, Université Bourgogne Franche-Comté, 21000 Dijon, France
- FCS Bourgogne-Franche Comté, LipSTIC LabEx, 21000 Dijon, France
- Institut Agro Dijon, 1 Esplanade Erasme, 21000 Dijon, France
| |
Collapse
|
2
|
Perrier V, Imberdis T, Lafon PA, Cefis M, Wang Y, Huetter E, Arnaud JD, Alvarez-Martinez T, Le Guern N, Maquart G, Lagrost L, Desrumaux C. Plasma cholesterol level determines in vivo prion propagation. J Lipid Res 2017; 58:1950-1961. [PMID: 28765208 PMCID: PMC5625119 DOI: 10.1194/jlr.m073718] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2016] [Revised: 07/28/2017] [Indexed: 12/27/2022] Open
Abstract
Transmissible spongiform encephalopathies are fatal neurodegenerative diseases with an urgent need for therapeutic and prophylactic strategies. At the time when the blood-mediated transmission of prions was demonstrated, in vitro studies indicated a high binding affinity of the scrapie prion protein (PrPSc) with apoB-containing lipoproteins, i.e., the main carriers of cholesterol in human blood. The aim of the present study was to explore the relationship between circulating cholesterol-containing lipoproteins and the pathogenicity of prions in vivo. We showed that, in mice with a genetically engineered deficiency for the plasma lipid transporter, phospholipid transfer protein (PLTP), abnormally low circulating cholesterol concentrations were associated with a significant prolongation of survival time after intraperitoneal inoculation of the 22L prion strain. Moreover, when circulating cholesterol levels rose after feeding PLTP-deficient mice a lipid-enriched diet, a significant reduction in survival time of mice together with a marked increase in the accumulation rate of PrPSc deposits in their brain were observed. Our results suggest that the circulating cholesterol level is a determinant of prion propagation in vivo and that cholesterol-lowering strategies might be a successful therapeutic approach for patients suffering from prion diseases.
Collapse
Affiliation(s)
- Véronique Perrier
- Université Montpellier and Inserm U1198, Montpellier, F-34095 France and EPHE, Paris, F-75007 France
| | - Thibaud Imberdis
- Université Montpellier and Inserm U1198, Montpellier, F-34095 France and EPHE, Paris, F-75007 France
| | - Pierre-André Lafon
- Université Montpellier and Inserm U1198, Montpellier, F-34095 France and EPHE, Paris, F-75007 France
| | - Marina Cefis
- Université Montpellier and Inserm U1198, Montpellier, F-34095 France and EPHE, Paris, F-75007 France
| | - Yunyun Wang
- Université Montpellier and Inserm U1198, Montpellier, F-34095 France and EPHE, Paris, F-75007 France.,Cellular Signaling Laboratory, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei, China
| | - Elisabeth Huetter
- Université Montpellier and Inserm U1198, Montpellier, F-34095 France and EPHE, Paris, F-75007 France
| | - Jacques-Damien Arnaud
- Etablissement Confiné d'Expérimentation A3/L3, CECEMA, US009 Biocampus, UMS 3426, Université Montpellier, Montpellier, F-34095 France
| | - Teresa Alvarez-Martinez
- Etablissement Confiné d'Expérimentation A3/L3, CECEMA, US009 Biocampus, UMS 3426, Université Montpellier, Montpellier, F-34095 France
| | - Naig Le Guern
- INSERM, LNC UMR866, F-21000 Dijon, France and LNC UMR866, Université Bourgogne Franche-Comté, F-21000 Dijon, France.,LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France
| | - Guillaume Maquart
- INSERM, LNC UMR866, F-21000 Dijon, France and LNC UMR866, Université Bourgogne Franche-Comté, F-21000 Dijon, France.,LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France
| | - Laurent Lagrost
- INSERM, LNC UMR866, F-21000 Dijon, France and LNC UMR866, Université Bourgogne Franche-Comté, F-21000 Dijon, France.,LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France.,University Hospital of Dijon, F-21000 Dijon, France
| | - Catherine Desrumaux
- Université Montpellier and Inserm U1198, Montpellier, F-34095 France and EPHE, Paris, F-75007 France .,LipSTIC LabEx, Fondation de Coopération Scientifique Bourgogne-Franche Comté, F-21000 Dijon, France
| |
Collapse
|
3
|
Si Y, Zhang Y, Chen X, Zhai L, Zhou G, Yu A, Cao H, Shucun Q. Phospholipid transfer protein deficiency in mice impairs macrophage reverse cholesterol transport in vivo. Exp Biol Med (Maywood) 2016; 241:1466-72. [PMID: 27037277 DOI: 10.1177/1535370216641218] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2015] [Accepted: 02/16/2016] [Indexed: 12/16/2022] Open
Abstract
Phospholipid transfer protein is expressed in various cell types and secreted into plasma, where it transfers phospholipids between lipoproteins and modulates the composition of high-density lipoprotein particles. Phospholipid transfer protein deficiency in vivo can lower high-density lipoprotein cholesterol level significantly and impact the biological quality of high-density lipoprotein. Considering high-density lipoprotein was a critical determinant for reverse cholesterol transport, we investigated the role of systemic phospholipid transfer protein deficiency in macrophage reverse cholesterol transport in vivo After the littermate phospholipid transfer protein KO and WT mice were fed high-fat diet for one month, they were injected intraperitoneally with (3)H-cholesterol-labeled and acLDL-loaded macrophages. Then the appearance of (3)H-tracer in plasma, liver, bile, intestinal wall, and feces over 48 h was determined. Plasma lipid analysis indicated phospholipid transfer protein deficiency lowered total cholesterol, high-density lipoprotein-C and apolipoprotein A1 levels significantly but increased triglyceride level in mice. The isotope tracing experiment showed (3)H-cholesterol of plasma was decreased by 68% for male and 62% for female, and (3)H-tracer of bile was decreased by 37% for male and 21% for female in phospholipid transfer protein KO mice compared with WT mice. However, there was no difference in liver, and (3)H-tracer of intestinal wall was increased by 43% for male and 27% for female. Finally, (3)H-tracer of fecal excretion in phospholipid transfer protein KO mice was reduced significantly by 36% for male and 43% for female during 0-24 h period, but there was no significant difference during 24-48 h period. Meanwhile, Western Blot analysis showed the expressions of reverse cholesterol transport -related protein liver X receptor α (LXRα), ATP binding cassette transporter A1, and cholesterol 7α-hydroxylase A1 were upregulated in liver of phospholipid transfer protein KO mice compared with WT mice. These data reveal that systemic phospholipid transfer protein deficiency in mice impairs macrophage-specific reverse cholesterol transport in vivo.
Collapse
Affiliation(s)
- Yanhong Si
- Key Laboratory of Atherosclerosis in Universities of Shandong and Institute of Atherosclerosis, Taishan Medical University, Taian 271000, China
| | - Ying Zhang
- Key Laboratory of Atherosclerosis in Universities of Shandong and Institute of Atherosclerosis, Taishan Medical University, Taian 271000, China
| | - Xiaofeng Chen
- Key Laboratory of Atherosclerosis in Universities of Shandong and Institute of Atherosclerosis, Taishan Medical University, Taian 271000, China
| | - Lei Zhai
- Key Laboratory of Atherosclerosis in Universities of Shandong and Institute of Atherosclerosis, Taishan Medical University, Taian 271000, China
| | - Guanghai Zhou
- Key Laboratory of Atherosclerosis in Universities of Shandong and Institute of Atherosclerosis, Taishan Medical University, Taian 271000, China
| | - Ailing Yu
- Taian Center Hospital, Taian 271000, China
| | - Haijun Cao
- Taian Center Hospital, Taian 271000, China
| | - Qin Shucun
- Key Laboratory of Atherosclerosis in Universities of Shandong and Institute of Atherosclerosis, Taishan Medical University, Taian 271000, China
| |
Collapse
|
4
|
Abstract
High-density lipoprotein (HDL) is considered to be an anti-atherogenic lipoprotein moiety. Generation of genetically modified (total body and tissue-specific knockout) mouse models has significantly contributed to our understanding of HDL function. Here we will review data from knockout mouse studies on the importance of HDL's major alipoprotein apoA-I, the ABC transporters A1 and G1, lecithin:cholesterol acyltransferase, phospholipid transfer protein, and scavenger receptor BI for HDL's metabolism and its protection against atherosclerosis in mice. The initial generation and maturation of HDL particles as well as the selective delivery of its cholesterol to the liver are essential parameters in the life cycle of HDL. Detrimental atherosclerosis effects observed in response to HDL deficiency in mice cannot be solely attributed to the low HDL levels per se, as the low HDL levels are in most models paralleled by changes in non-HDL-cholesterol levels. However, the cholesterol efflux function of HDL is of critical importance to overcome foam cell formation and the development of atherosclerotic lesions in mice. Although HDL is predominantly studied for its atheroprotective action, the mouse data also suggest an essential role for HDL as cholesterol donor for steroidogenic tissues, including the adrenals and ovaries. Furthermore, it appears that a relevant interaction exists between HDL-mediated cellular cholesterol efflux and the susceptibility to inflammation, which (1) provides strong support for the novel concept that inflammation and metabolism are intertwining biological processes and (2) identifies the efflux function of HDL as putative therapeutic target also in other inflammatory diseases than atherosclerosis.
Collapse
Affiliation(s)
- Menno Hoekstra
- Division of Biopharmaceutics, Gorlaeus Laboratories, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333CC, Leiden, The Netherlands,
| | | |
Collapse
|